About BioSapien
Our Story
BioSapien was founded in 2018 by a physician who had seen the same problem from both sides of the operating table: cancer drugs are delivered to the whole body to treat one part of it.
That premise led to MediChip™ — a patented, biodegradable drug-delivery platform that places therapy at the tumor site and releases it locally over weeks. Built from advanced biomaterials using 3D printing, MediChip™ is engineered to cut systemic exposure while sustaining treatment exactly where it's needed.
Since founding, BioSapien has moved from scientific concept to clinical-stage company. We've completed GMP manufacturing, cleared IND, built a global patent portfolio, and secured backing from life sciences global investors. MediChip™-5-FU is now entering first-in-human study in locally advanced rectal cancer.
Cancer is the starting point, not the boundary. The underlying principle applies wherever medicine is needed: deliver it where it's required, for as long as it's required, and nowhere else.
“Our mission is to redefine how cancer therapies are delivered—bringing treatment directly to where it's needed while reducing unnecessary burden on patients.”
Khatija Ali
CEO & Founder
Building a better way to deliver cancer therapy.
01
Mission
To deliver cancer therapy where it's needed and nowhere else. Our biodegradable MediChip™ implant places chemotherapy at the tumor site, sparing patients the systemic toxicity that defines current treatment — with 1 million patients treated by 2035.
02
Vision
Localized delivery as the standard of care in solid tumors.
Help shape the future of localizedcancer therapy.
Whether you're a pharmaceutical company, research institution, clinical investigator, or strategic partner, we're building the next generation of localized oncology treatments together.
.avif)